Amneal Pharmaceuticals (NASDAQ:AMRX) said on Thursday the US Food and Drug Administration has approved its romidepsin injection solution, 27.5 mg/5.5 mL, in single-dose, ready-to-use vials. The product is eligible for Competitive Generic Therapy (CGT) designation, giving Amneal 180 days of market exclusivity.